STOCK TITAN

Quantum-Si Added to the Nasdaq Biotechnology Index

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Quantum-Si (Nasdaq: QSI) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of its annual reconstitution, effective December 20, 2021. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities based on specific eligibility criteria such as market capitalization and trading volume. Quantum-Si specializes in protein sequencing technology, aiming to enhance drug discovery and diagnostics through its innovative semiconductor chip designed for single molecule sequencing.

Positive
  • Inclusion in the Nasdaq Biotechnology Index enhances Quantum-Si's visibility and credibility among investors.
  • The company focuses on cutting-edge protein sequencing technology, which is crucial for advancing drug discovery.
Negative
  • The press release contains forward-looking statements, indicating risks and uncertainties that could impact the company's performance.
  • The company faces challenges such as competition and the ability to secure future financing for development.

GUILFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences tools company commercializing a unique protein sequencing platform, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition is based on the results of the annual reconstitution of the index announced by Nasdaq on December 10, 2021 and will become effective prior to the U.S. market open on Monday, December 20, 2021.

Launched in 1993, the Nasdaq Biotechnology Index is a modified market-cap weighted index designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.

For more information about the Nasdaq Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Quantum-Si

Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on The Nasdaq Stock Market LLC; the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development and commercialization of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contacts

Juan Avendano

Mike Cavanaugh

(617) 877-9641

ir@quantum-si.com

Media Contact

Cammy Duong

(203) 682-8380

QSI-PR@westwicke.com

Source: Quantum-Si Incorporated

FAQ

When was Quantum-Si added to the Nasdaq Biotechnology Index?

Quantum-Si was added to the Nasdaq Biotechnology Index effective December 20, 2021.

What is the significance of Quantum-Si joining the Nasdaq Biotechnology Index?

Joining the Nasdaq Biotechnology Index increases Quantum-Si's visibility and credibility in the biotech sector.

What technology does Quantum-Si specialize in?

Quantum-Si specializes in protein sequencing technology aimed at enhancing drug discovery and diagnostics.

What risks does Quantum-Si mention in their press release?

The company outlines risks related to competition, financing needs, and the impact of market conditions.

Quantum-Si Incorporated

NASDAQ:QSI

QSI Rankings

QSI Latest News

QSI Stock Data

130.23M
122.42M
19.91%
36.41%
4.15%
Medical Devices
Measuring & Controlling Devices, Nec
Link
United States of America
BRANFORD